Aibotics Q2 Loss Widens; Working Capital Deficit Hits $4.9M, Shares Outstanding Surge 48%
AIBT sits 33% above its 52-week low of $0 on light trading volume (0.3× avg).
Summary
Aibotics' Q2 2026 10-Q shows a widening net loss, a $4.9M working capital deficit, and a 48% surge in shares outstanding, with substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · AIBT
-
Q2 Net Loss Widens
Net loss for Q2 2026 was $536,968, up from $486,149 in Q2 2025. Six-month loss was $955,073.
-
Working Capital Deficit Grows
Working capital deficit reached $4,875,875 at June 30, 2026, up from $4,564,798 at December 31, 2025.
-
Going Concern Doubt Reiterated
Management states substantial doubt about the company's ability to continue as a going concern within one year.
-
Massive Share Dilution
Common shares outstanding increased 48.4% to 722.5 million during H1 2026, with an additional 127.7 million shares issued after quarter-end, bringing total to 850.2 million.
Analysis · AIBT · Life Sciences
Aibotics reported a Q2 net loss of $536,968, bringing the six-month loss to $955,073. The company's working capital deficit expanded to $4,875,875, and management reiterated substantial doubt about its ability to continue as a going concern. The share count ballooned 48% during the first half of 2026, with an additional 127.7 million shares issued after quarter-end, signaling aggressive dilution to fund operations and settle liabilities.
At the time of this filing, AIBT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $272.8K. The 52-week trading range was $0.00 to $0.01. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.